Iatrogenic comorbidity in childhood and adolescence: New insights from the use of antidepressant drugs

Emanuela Offidani, Giovanni A. Fava, Nicoletta Sonino

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

The term "iatrogenic comorbidity" refers to unfavorable modifications in the course of an illness, with regard to its characteristics and responsiveness, which may be related to previous treatments. Some iatrogenic adverse events arising from either pharmacotherapy or psychotherapy cannot be subsumed under the traditional rubric of adverse effects and require careful evaluation. Children and adolescents are generally more likely to experience adverse health consequences after drug treatment. The use of antidepressant drugs in this age group may cause potential long-term detrimental effects, such as mood elevation that does not subside when drugs are discontinued and may predispose to the development of a bipolar disorder. The concept of iatrogenic comorbidity in children and adolescents has heuristic value in weighing potential benefits and risks associated particularly with psychotropic treatments.

Original languageEnglish (US)
Pages (from-to)769-774
Number of pages6
JournalCNS Drugs
Volume28
Issue number9
DOIs
StatePublished - Sep 2014

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Iatrogenic comorbidity in childhood and adolescence: New insights from the use of antidepressant drugs'. Together they form a unique fingerprint.

Cite this